LFCYF Stock UPDATES Veloxis Pharmaceutic (LFCYF) 0.3290 08/30/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Veloxis Pharmaceutic (LFCYF) 0.3290 $LFCYF

Envarsus® Receives European Marketing Authorization for Treatment of Both Kidney and Liver Transplant Patients
PR Newswire - Mon Jul 28, 1:30AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) and Chiesi Farmaceutici S.p.A. today announced that the European Commission (EC) has granted marketing authorization for Envarsus® for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union (EU).

Envarsus® XR Demonstrates Lower Treatment Failure Rate in African-Americans Compared to Twice-Daily Tacrolimus (Prograf®)
PR Newswire - Mon Jun 30, 6:00AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, demonstrated a lower treatment failure rate in African-Americans compared with twice-daily tacrolimus (Prograf®). These study data will be presented at the World Transplant Congress (WTC), July 26 to 31, in San Francisco, in a presentation entitled "Lower Treatment Failures in Blacks and Older De Novo and Stable Kidney Transplant Recipients Treated with Envarsus XR Once-Daily MeltDose Tablets vs. Twice Daily Prograf Capsules." The presentation will occur at 6:30 pm - 8:00 PM, Sunday, July 27th, 2014. There are several additional presentations on Envarsus XR at WTC in addition to the subgroup analysis on African-American patients, which are summarized below.

Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients
PR Newswire - Mon Jun 23, 10:50AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that two-year results of the pivotal Phase 3 clinical trial, Study 3002, of Envarsus® XR (tacrolimus extended-release tablets) in de novo kidney transplant patients continued to demonstrate non-inferiority compared to tacrolimus capsules (Prograf®; Astellas Pharma). Data will be presented in a late-breaker session at the World Transplant Congress (WTC) in San Francisco, entitled "Two-Year Results of Envarsus (Once-daily MeltDose Tacrolimus Tablets) vs Prograf (Twice-daily Tacrolimus Capsules): A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study" at 6:30 p.m. PDT on July 27th.

U.S. FDA Accepts Veloxis' New Drug Application for Envarsus® for the Prevention of Organ Rejection in Kidney Transplant Patients
PR Newswire - Thu Mar 13, 12:44PM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the U.S. FDA accepted for standard review the company's New Drug Application (NDA) for Envarsus® for the prevention of organ rejection in adult kidney transplant patients. Envarsus® is Veloxis' once-daily tacrolimus based on the company's proprietary MELTDOSE technology.

Veloxis Promotes John Weinberg to Chief Operating Officer
PR Newswire - Thu Mar 06, 8:48AM CST
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that John Weinberg, M.D., currently chief commercial officer of Veloxis, has been promoted to chief operating officer.

Veloxis Pharmaceuticals publishes Annual Report 2013
PR Newswire - Wed Mar 05, 7:02AM CST
Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis' today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2013. The annual report has been prepared in accordance with International Financial Reporting Standards as adopted by the EU and additional Danish disclosure requirements for annual reports of listed companies.

Veloxis Pharmaceuticals Receives Notice of Allowance from U.S. Patent Office for Diurnal-Independent Administration of Envarsus®
PR Newswire - Wed Jan 08, 10:25AM CST
Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/167,420, a patent which covers the diurnal-independent administration of Envarsus®.

Veloxis Pharmaceuticals Announces NDA Submission for Envarsus® in Kidney Transplant Recipients
PR Newswire - Mon Dec 30, 2:00AM CST
Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® (formerly LCP-Tacro(TM)) for the prevention of organ rejection in kidney transplant recipients. The submission is based on the entire data set from the company's clinical development program that comprised 25 studies and enrolled over 1000 patients, including two pivotal clinical trials, studies 3001 and 3002. In the two pivotal trials, Envarsus® given once-daily met the primary endpoint of demonstrating comparable efficacy and safety compared to twice-daily tacrolimus (Prograf®, Astellas Pharma, Inc.). In the largest study, Study 3002, Envarsus® was shown to have a primary efficacy failure rate of 18.3% vs 19.6% with Prograf therapy. The differences between the treatments was well-within the pre-defined 10% non-inferiority margin. The study was conducted under a Special Protocol Agreement with the FDA. Envarsus® has been granted Orphan Drug status by the FDA for prophylaxis of rejection for kidney transplant recipients.

Veloxis Pharmaceuticals Envarsus® Granted Orphan Drug Status by U.S. Food and Drug Administration for Kidney Transplant Rejection Prophylaxis
PR Newswire - Tue Dec 24, 6:00AM CST
Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that Envarsus® was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. Envarsus® is Veloxis' once-daily formulation of tacrolimus employing the company's proprietary MeltDose® technology.

Phase III Clinical Study Data Demonstrating LCP-Tacro(TM)'s Comparable Efficacy and Safety to Twice-Daily Tacrolimus Presented at the European Society for Organ Transplantation
PR Newswire - Wed Sep 04, 7:00AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the 3002, randomized, double-blind, double-dummy, Phase III study in 543 de novo kidney transplant patients will be presented at the European Society for Organ Transplantation as a late-breaker oral presentation at 8:30 a.m. CEST, Sept. 9, in Vienna. Veloxis' once-daily LCP-Tacro(TM), now with the trade name of Envarsus®, demonstrated comparable efficacy and safety compared to twice-daily tacrolimus (Prograf®).

Veloxis Announces Positive Results of 3002 Study: LCP-Tacro(TM) Meets Primary Efficacy and Safety Endpoints in de Novo Kidney Transplant Patients
PR Newswire - Thu Jun 27, 11:26AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced LCP-Tacro(TM) successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002. The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf® as the comparator, met its primary efficacy and primary safety endpoints. The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.

European Medicines Agency (EMA) Accepts Veloxis' Marketing Authorization Application (MAA) for LCP-Tacro for Treatment of Kidney Transplant Patients
PR Newswire - Tue May 21, 3:30PM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the European Medicines Agency (EMA) accepted for review the company's Marketing Authorization Application (MAA) to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union. Veloxis expects the decision from the European Union in 2014.

Final STRATO Clinical Study Data Demonstrates Potential for LCP-Tacro(TM) to Improve Tacrolimus-Induced Tremors
PR Newswire - Mon May 20, 2:00AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-Tacro(TM) to improve tacrolimus-induced tremors in stable kidney transplant patients. The study, Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO(TM) (STRATO) clinical trial, was presented at the 13th American Transplant Congress, Abstract #B1022, on Sunday, May 19, 2013 in Seattle.

Veloxis Announces Submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) for LCP-Tacro(TM) for Treatment of Kidney Transplant Patients
PR Newswire - Mon Apr 29, 6:49AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.

Veloxis' Phase 3 Trial of LCP-Tacro(TM) in Stable Kidney Transplant Patients, the 3001 Study, Published Online in the American Journal of Transplantation
PR Newswire - Thu Jan 03, 7:00AM CST
Veloxis Pharmaceuticals A/S today is announcing that the LCP-Tacro Phase III clinical trial in stable kidney transplant patients, the 3001 study, has been published online in the American Journal of Transplantation. The article reports on the randomized, controlled, multicenter Phase III trial, which demonstrated that LCP-Tacro dosed once-daily was not inferior to the current leading transplant drug, Prograf®, dosed twice-daily. Non-inferiority was determined by a composite endpoint, measured over a year of follow up that included death, graft failure, biopsy-proven acute rejection or loss to follow-up.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 38

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 179

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 21

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 53

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
OFRM Recall Leaves Investors Facing Hard Questions

Updated Category News Views 60

Nothing wrecks a young consumer brand’s glow faster than a recall involving toddlers, and Once Upon A Farm has just learned that lesson in the ugliest possible way. On November 2, 2026, shares of NYSE:OFRM fell 37% to close at $9.44. That left the stock roughly 47% below its $18 IPO price. Those are not the garden-variety bruises of a weak quarter. That is the market...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 156

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Gildan Lawsuit Puts Revenue Controls Under a Harsh Light

Updated Category News Views 61

Receivables have a nasty way of becoming everybody’s problem once the story cracks. Gildan Activewear is staring at that uncomfortable reality after a securities fraud class action was filed on behalf of investors who bought or acquired shares between February 19, 2025 and June 15, 2026. The case, Cortez v. Gildan Activewear Inc., is pending in the U.S. District Court...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 80

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 113

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 87

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading

Top 5 Most Recently Viewed Articles

Gen Z's Evolving College Search: The Impact of Politics

Updated Category News Views 205

Understanding Gen Z's College Decisions In recent times, higher education choices have become a significant reflection of societal shifts, especially concerning political climates. A new report from an education company highlights how politics influence college decisions among Gen Z students. This demographic, characterized as more conscious of political environments,...

Continue Reading
LiveWire and KYMCO Unveil Electric Maxi-Scooter Plans

Updated Category News Views 46

LiveWire and KYMCO Strengthen Partnership LiveWire, a prominent figure in the electric motorcycle industry, has exciting news to share. In collaboration with KYMCO, a highly regarded powersports manufacturer, the two companies are working to amplify their strategic alliance. This partnership focuses on introducing an electric maxi-scooter tailored specifically for the...

Continue Reading
Rudholm Group's Compliance Portal: Regulatory Game Changer or Just Noise?

Updated Category News Views 180

Rudholm Group just unveiled its new Compliance Portal on February 18, 2026, aiming to tackle the labyrinth of ever-evolving regulations in the apparel sector. You know how it is—every corner of this industry is drowning in red tape, and brands are gasping for air trying to keep up with local laws that change faster than a fashion trend. The CEO, Dennis Lau, stated they...

Continue Reading
Teva's Upcoming Conference Call for Q4 Financial Results

Updated Category News Views 74

Teva's Upcoming Conference Call for Q4 Financial Results TEL AVIV, Israel — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced an important event for investors and stakeholders. The company plans to release its fourth quarter 2025 financial results on a specific date. Following the release, Teva will host a conference call and a live webcast to...

Continue Reading
Understanding the Recent Decline of Moderna's Stock and Future Prospects

Updated Category News Views 178

Moderna's Stock Takes a Dive: Key Factors Explained Moderna Inc (NASDAQ: MRNA) has faced a significant drop in its stock value recently, prompting investors to seek clarity on the reasons behind this decline. The company has been in the news with some critical developments that have overshadowed its achievements in the medical field. Recent Clinical Setbacks The primary...

Continue Reading